Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...96979899100101102103104105106...10651066»
  • ||||||||||  budesonide / Generic mfg.
    Review, Journal:  IgA nephropathy. (Pubmed Central) -  Dec 5, 2023   
    For those at high risk of disease progression, the 2021 KDIGO Clinical Practice Guideline suggests considering a 6-month course of systemic corticosteroid therapy; however, the efficacy of systemic steroid treatment is under debate and serious adverse effects are common. Advances in understanding the pathophysiology of IgAN have led to clinical trials of novel targeted therapies with acceptable safety profiles, including SGLT2 inhibitors, endothelin receptor blockers, targeted-release budesonide, B cell proliferation and differentiation inhibitors, as well as blockade of complement components.
  • ||||||||||  revumenib (SNDX-5613) / Syndax Pharma
    Enrollment open, Combination therapy:  A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (clinicaltrials.gov) -  Dec 5, 2023   
    P2,  N=78, Recruiting, 
    Advances in understanding the pathophysiology of IgAN have led to clinical trials of novel targeted therapies with acceptable safety profiles, including SGLT2 inhibitors, endothelin receptor blockers, targeted-release budesonide, B cell proliferation and differentiation inhibitors, as well as blockade of complement components. Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Cushing's syndrome with inhaled corticosteroid: Drug interactions to avoid (Pubmed Central) -  Dec 4, 2023   
    We report the clinical case of a 29-year-old woman with a past history of asthma treated with inhaled fluticasone propionate (FP), chronic pulmonary aspergillosis and allergic bronchopulmonary aspergillosis (ABPA) treated with itraconazole (ITZ), and Mycobacterium xenopi infection treated with moxifloxacin (MXF), ethambutol (EMB) and clarithromycin (CLR)...Following on the one hand cessation of FP and ITZ and on the other hand hydrocortisone supplementation, evolution was favorable...If possible, FP should be avoided in patients being treated with CYP3A4 inhibitors. Due to its differing physicochemical properties, beclometasone may be considered as the safest therapeutic alternative.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal, IO biomarker:  IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma. (Pubmed Central) -  Dec 4, 2023   
    The cell lines may be useful in developing immunotherapies directed against BAFF-R and TACI, though not BCMA, and may also be a good model for studying dexamethasone resistance. These data indicate that the IL6Myc model is useful for studying development of aggressive MM and for developing new treatments against such forms of the disease.
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  The post-COVID stress syndrome: from the three-stage stress response of Hans Selye to COVID-19. (Pubmed Central) -  Dec 4, 2023   
    Thus, these 'natural phenomena' in clinical medicine, unfortunately confirmed Selye's studies in experimental animals several decades ago. Still, the good news is that astute clinicians empirically recognized this and started to give potent synthetic glucocorticoids such as dexamethasone to severe COVD-19 patients and this beneficial effect of exogenous corticoids has been extensively confirmed in the scientific literature.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  A spatiotemporal drug release scaffold with antibiosis and bone regeneration for osteomyelitis. (Pubmed Central) -  Dec 4, 2023   
    Still, the good news is that astute clinicians empirically recognized this and started to give potent synthetic glucocorticoids such as dexamethasone to severe COVD-19 patients and this beneficial effect of exogenous corticoids has been extensively confirmed in the scientific literature. The findings suggested that this spatiotemporal drug release scaffold had promising potential for osteomyelitis therapy.
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Advancing Preoperative Strategies for Thyroidectomy in Graves' Disease: A Narrative Review. (Pubmed Central) -  Dec 4, 2023   
    Nevertheless, discrepancies do become apparent in aspects such as potassium iodide (SSKI) course duration and preoperative dexamethasone administration. By understanding these differing approaches, healthcare professionals can more effectively manage Graves' disease prior to surgery, resulting in improved patient outcomes and enhanced surgical success.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Cimifugin inhibits adipogenesis and TNF-?-induced insulin resistance in 3T3-L1 cells. (Pubmed Central) -  Dec 4, 2023   
    3T3-L1 adipocytes were treated with 3-isobutyl-1-methyl-xanthine, dexamethasone, and insulin or cimifugin and then Oil Red O staining and intracellular triglyceride content detection were performed to assess adipogenesis...Moreover, cimifugin reduced TNF-?-induced pro-inflammatory factors production and phospho-P65 expression, and MAPK pathway activation in the 3T3-L1 adipocytes. These findings suggested that cimifugin might be useful for the prevention and therapy of obesity-related IR and inflammation.
  • ||||||||||  Fodosine (forodesine) / Mundipharma, BioCryst
    Journal:  Plant nucleoside N-ribohydrolases: riboside binding and role in nitrogen storage mobilization. (Pubmed Central) -  Dec 4, 2023   
    We report the crystal structure of Zea mays NRH2b (subclass II) and NRH3 (subclass I) in complexes with the substrate analog forodesine...Dexamethasone-inducible ZmNRH overexpressor lines of Arabidopsis thaliana, as well as double nrh knockout lines of moss Physcomitrium patents, reveal a fine control of adenosine in contrast to other ribosides...We observe changes in the pathways related to nitrogen-containing compounds such as ?-alanine and several polyamines, which allow plants to reprogram their metabolism to escape stress. Taken together, crop plant breeding targeting enhanced NRH-mediated nitrogen recycling could therefore be a strategy to enhance plant growth tolerance and productivity under adverse growth conditions.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma. (Pubmed Central) -  Dec 4, 2023   
    Taken together, crop plant breeding targeting enhanced NRH-mediated nitrogen recycling could therefore be a strategy to enhance plant growth tolerance and productivity under adverse growth conditions. Altogether, TRIP12 induces K63-linked site-specific polyubiquitination of EZH2 for stabilization, which promotes ENKTL cell migration and could be targeted by dexamethasone treatment.
  • ||||||||||  budesonide ER / Generic mfg.
    Trial initiation date:  Efficacy and Safety of Budesonide MMX (clinicaltrials.gov) -  Dec 4, 2023   
    P2,  N=80, Not yet recruiting, 
    Altogether, TRIP12 induces K63-linked site-specific polyubiquitination of EZH2 for stabilization, which promotes ENKTL cell migration and could be targeted by dexamethasone treatment. Initiation date: Sep 2023 --> Jan 2024
  • ||||||||||  hydrocortisone / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  ROSES: Role Of Sensitivity to neuroEndocrine Systems in Social Decisions (clinicaltrials.gov) -  Dec 4, 2023   
    P4,  N=104, Not yet recruiting, 
    Initiation date: Sep 2023 --> Jan 2024 Trial completion date: Dec 2024 --> Mar 2025 | Initiation date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2024 --> Mar 2025
  • ||||||||||  hydrocortisone / Generic mfg.
    Review, Journal:  Bilateral adrenal hemorrhage: learning notes from clinical practice and literature review. (Pubmed Central) -  Dec 3, 2023   
    On 5 years' follow-up from the acute event, the second patient's adrenal function had returned to normal, and he has not needed further adrenal replacement therapy; the first patient however demonstrated persistence of adrenal failure requiring replacement therapy. In this paper, through our experience and a literature analysis, we will aim to outline some clues to identify patients at potential risk of bilateral adrenal hemorrhage.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
    Journal:  Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14). (Pubmed Central) -  Dec 3, 2023   
    Similarly, Patient 2, refractory to frontline bortezomib-thalidomide-dexamethasone therapy, attained CR following a transition to bortezomib-dexamethason-venetoclax treatment...The outcomes observed in our patients suggest that venetoclax-based therapy holds substantial promise as an effective treatment option for this specific genetic subgroup. Furthermore, the similarities in treatment response between t(11;14) and t(6;14) translocation subgroups highlight the importance of personalized approaches targeting specific genetic abnormalities to optimize therapeutic outcomes.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  A human 3D immune competent full-thickness skin model mimicking dermal dendritic cell activation. (Pubmed Central) -  Dec 3, 2023   
    Noteworthy, the expression of CD54 and CD86 could be suppressed by dexamethasone treatment on isolated iDCs (CD54: 1.3-fold; CD86: 2.1-fold) as well as on the tissue-integrated iDCs (CD54: 1.4-fold; CD86: 1.6-fold). In conclusion, we were able to integrate THP-1-derived iDCs as functional dermal dendritic cell surrogates allowing the qualitative identification of potential sensitizers on the one hand, and drug candidates that potentially suppress sensitization on the other hand in a 3D human skin model corresponding to the 3R principles ("replace", "reduce" and "refine").